This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Moderna (MRNA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
U.S. Dollar Sees First Drop Since 2017: ETFs & Stocks to Buy
by Sweta Killa
The super-easy policies by the Fed and the central government as well as a series of vaccine development have pushed the U.S. dollar down.
Moderna (MRNA) Raises COVID-19 Vaccine Production Target
by Zacks Equity Research
Moderna (MRNA) raises lower end of its global manufacturing target for its coronavirus vaccine by 20% for 2021. The company still aims to deliver up to one billion doses in the year.
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study
by Zacks Equity Research
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
Tech Finishes as the Strongest Sector in 2020
by Zacks Equity Research
Tech Finishes as the Strongest Sector in 2020
Markets Pick Up in 2021 Right Where They Left Off
by Mark Vickery
The Dow is up more than 110 points, the Nasdaq +60 and the S&P 500 +15. It appears there is more appetite at the start of the year to shoot for new all-time highs in the market.
5 Momentum Stocks Bargain Hunters Would Love Chasing
by Nilanjan Choudhury
To tap the market's rally, it will be prudent to invest in momentum stocks that are still cheap. Our choices are Winnebago Industries (WGO), Fiat Chrysler (FCAU), FedEx (FDX), Williams-Sonoma (WSM) and Lennar (LEN).
5 Little-Known Stocks Under $20 Analysts Recommend Buying
by Anindya Barman
We recommend a few lesser-known stocks that hold promise for high returns this year. ADTN, AMEH, ATEC, DFIN and DGII fit the bill.
Top ETF Stories of Fourth-Quarter 2020
by Sanghamitra Saha
The year 2020 as a whole could easily be attributed to the COVID-19 outbreak.
5 Big ETF Stories of 2020 Worth Watching in 2021
by Sweta Killa
We discuss some of the events that dominated the headlines in 2020 and are worth watching in 2021.
AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK
by Zacks Equity Research
AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.
4 Best Performing Sector ETFs of December
by Sweta Killa
Despite the surge in coronavirus cases, December has been kind for the U.S. stock market with the major indices enjoying a historic rally.
Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results
by Zacks Equity Research
Arcturus (ARCT) releases not so encouraging data from its phase I/II and preclinical study on its coronavirus vaccine candidate, ARCT-021.
The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Ultragenyx Pharma, Fate Therapeutics, Intellia Therapeutics, and Mersana Therapeutics
5 Factors Indicating That Oil is Poised for a Run-Up in 2021
by Nilanjan Choudhury
As a proof of the improving energy environment, refining biggies like Marathon Petroleum (MPC) and Phillips 66 (PSX) experienced sequential increase in utilization during the third quarter.
Wall Street Stories That Hit Headlines in 2020
by Sweta Killa
With super-easy policies and vaccination, small-cap stocks like Liquidity Services (LQDT) and cyclical stocks like Nexstar Media (NXST), Deere & Company (DE) and BHP Billiton (BBL) are expected to benefit the most.
5 Biotech Stocks That Have Gained More Than 200% in 2020
by Kinjel Shah
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
5 Stocks That Could Hit Several New Highs in 2021
by Sandip Chakraborty
Given the upbeat sentiments in the market, FedEx (FDX), Deere (DE), D.R. Horton (DHI), Fortescue (FSUGY) and Fiat Chrysler (FCAU) are expected to give good returns to investors in 2021.
5 Sector ETFs That Beat the Market in 2020
by Sweta Killa
With historic twists and turns, 2020 has turned out to be a banner year.
3 Restaurant Stocks to Gain Big With the Vaccine Rollout
by Zacks Equity Research
Restaurant industry is likely to benefit from the vaccine rollout. Following the vaccine rollout, dine-in option should become safe and traffic is likely to increase.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.
by Zacks Equity Research
Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
Evergreen Tree of ETFs to Lighten Your Christmas
by Sweta Killa
The Christmas tree of top-ranked ETFs to brighten 2021 is now ready for investors. May it spread cheer!
5 Bank Stocks Set to Rebound With Vaccine-Driven Economic Recovery
by Radhika Saraogi
Improving lending scenarios and restoration of normal activities in 2021, with the help of coronavirus vaccines rollout, will likely help banks like JPMorgan (JPM), Bank of Hawaii (BOH), Bank OZK (OZK), UMB Financial (UMBF) and Synovus (SNV) witness a rebound.
3 Airlines Stocks to Gain as the Economy Looks to Fully Reopen
by Zacks Equity Research
Rollout of the vaccine along with an expected fiscal stimulus is sure to boost the airlines industry, making it prudent to watch out for names like Mesa Air Group (MESA) and Spirit Airlines (SAVE).